CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
SUBLICENSE REVENUE	$ 2,000	$ 0	$ 2,000	$ 0
OPERATING EXPENSES:
Sublicense transaction costs	254	0	254	0
General and administrative	84	102	313	215
Research and development	322	112	623	379
Total operating expenses	660	214	1,190	594
Income (loss) after operating expenses	1,340	(214)	810	(594)
Interest and other income (expense), net	(62)	6	(122)	(9)
Income (loss) from operations before taxes	1,278	(208)	688	(603)
Income tax benefit	0	2	3	10
NET INCOME (LOSS)	1,278	(206)	691	(593)
Less: Net Income (Loss) attributable to the noncontrolling interest	0	0	0	0
Net Income (Loss) attributable to Capstone Therapeutics Corp. stockholders	$ 1,278	$ (206)	$ 691	$ (593)
Per Share Information:
Net Income (Loss), basic and diluted, attributable to Capstone Therapeutic Corp. stockholders	$ 0.02	$ (0.01)	$ 0.01	$ (0.01)
Basic and diluted shares outstanding	54,385	40,885	54,385	40,885